Ascendis Pharma Announces Resubmission Of TransCon PTH NDA For Adults With Hypoparathyroidism Expected Before Mid-November 2023
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S (NASDAQ:ASND) plans to report its Q3 2023 financial results and provide a business update on November 7, 2023. The company also announced its intention to resubmit its NDA for TransCon PTH for adults with hypoparathyroidism to the FDA before mid-November 2023. A conference call and webcast will be hosted on the same day to discuss the financial results and operations.

October 31, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendis Pharma's announcement of its Q3 2023 financial results and the resubmission of its NDA for TransCon PTH could potentially impact its stock price.
The announcement of financial results can often lead to fluctuations in a company's stock price, depending on whether the results meet, exceed, or fall short of expectations. Additionally, the resubmission of the NDA for TransCon PTH indicates progress in Ascendis Pharma's product pipeline, which could be viewed positively by investors. However, the actual impact will depend on the details revealed during the conference call.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100